These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 1284786)
1. Coordinate loss of growth regulatory factors following castration of rats carrying the Dunning R3327 G prostatic tumor. Rubenstein M; Shaw M; Targonski P; McKiel CF; Dubin A; Guinan PD Clin Physiol Biochem; 1992; 9(2):47-50. PubMed ID: 1284786 [TBL] [Abstract][Full Text] [Related]
2. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss. Humphries JE; Isaacs JT Cancer Res; 1982 Aug; 42(8):3148-56. PubMed ID: 7093958 [TBL] [Abstract][Full Text] [Related]
3. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Brändström A; Westin P; Bergh A; Cajander S; Damber JE Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987 [TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Pinski J; Reile H; Halmos G; Groot K; Schally AV Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203 [TBL] [Abstract][Full Text] [Related]
5. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Joseph IB; Isaacs JT Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270 [TBL] [Abstract][Full Text] [Related]
6. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749 [TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer. English HF; Heitjan DF; Lancaster S; Santen RJ Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359 [TBL] [Abstract][Full Text] [Related]
8. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation. Pollack A; Block NL; Stover BJ; Irvin GL Cancer Res; 1985 Mar; 45(3):1052-7. PubMed ID: 3971360 [TBL] [Abstract][Full Text] [Related]
9. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Nickerson T; Miyake H; Gleave ME; Pollak M Cancer Res; 1999 Jul; 59(14):3392-5. PubMed ID: 10416600 [TBL] [Abstract][Full Text] [Related]
10. Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment. Lindström P; Bergh A; Holm I; Damber JE Prostate; 1996 Oct; 29(4):209-18. PubMed ID: 8876704 [TBL] [Abstract][Full Text] [Related]
11. R3327 prostate adenocarcinoma clonogenic cells: epithelial properties and hormone response. Dibner JJ; Nakeff A J Natl Cancer Inst; 1983 Jun; 70(6):1057-66. PubMed ID: 6574275 [TBL] [Abstract][Full Text] [Related]
12. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Landström M; Damber JE; Bergh A Cancer Res; 1994 Aug; 54(16):4281-4. PubMed ID: 7913874 [TBL] [Abstract][Full Text] [Related]
13. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058 [TBL] [Abstract][Full Text] [Related]
14. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594 [TBL] [Abstract][Full Text] [Related]
15. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma. Ip MM; Milholland RJ; Rosen F Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787 [TBL] [Abstract][Full Text] [Related]
16. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Joseph IB; Nelson JB; Denmeade SR; Isaacs JT Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654 [TBL] [Abstract][Full Text] [Related]
17. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153 [TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion. Ip MM; Sylvester PW; Schenkel L Cancer Res; 1986 Apr; 46(4 Pt 1):1735-40. PubMed ID: 3948162 [TBL] [Abstract][Full Text] [Related]
19. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Isaacs JT Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976 [TBL] [Abstract][Full Text] [Related]
20. Immunoregulatory markers in rats carrying Dunning R3327 H, G, or MAT-LyLu prostatic adenocarcinoma variants. Rubenstein M; Shaw MW; McKiel CF; Ray PS; Guinan PD Cancer Res; 1987 Jan; 47(1):178-82. PubMed ID: 3491674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]